Society Logo
ME/CFS Australia Ltd
Please click here to donate ME/CFS Australia (SA) Inc
 
 
Facebook
 
ME/CFS AUSTRALIA (SA) INC

Registered Charity 698

Email:
sacfs@sacfs.asn.au

Mailing address:
PO Box 28,
Hindmarsh,
South Australia 5007

Office:
Suite 506,
North Terrace House,
19 North Terrace,
Hackney, SA, 5069


Phone:
1300 128 339

Office Hours:
Wednesdays, 11am-3pm

ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.

Disclaimer

ME/CFS Australia (SA) Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
PDF Application Form (PDF, 277KB)
Why become a member?

Pfizer's Lyrica Pain Drug Fails FDA Test For Fibromyalgia In Adolescents

Monday 16 March 2015

 

From Proactive Investors USA and Canada:

 

Drugs
 

Pfizer's Lyrica pain drug fails FDA test for fibromyalgia in adolescents

By Alessandro Bruno
Fri 13 March 2015 12:51 pm

Pfizer's (NYSE:PFE) Lyrica pain drug has failed to meet U.S. Food and Drug Administration (FDA) requirements in a post-marketing study testing the treatment of fibromyalgia in adolescents.

The main goal of the FDA-mandated test, the results of which were announced after market close on March 12, was to evaluate the safety and effectiveness of Lyrica in treating teenagers (12-17 years) suffering from fibromyalgia (FM).

The study concluded that no statistically significant difference between Lyrica and the placebo arm was observed in the mean pain score.

Pfizer conducted the study, which enrolled 107 adolescent patients in a randomized, double-blind, placebo-controlled test that lasted 15 weeks, throughout the U.S., Europe and Asia. This study is the first large pharmacological treatment study to be completed in this study population.

"Lyrica has more than 10 years of real world experience supporting the needs of patients and remains an important treatment choice for healthcare professionals," said senior VP and head of Global Medicines Development for the Pfizer Global Innovative Pharmaceutical business, Steve Romano.

"These results do not change the established benefit of Lyrica for its approved indications, including fibromyalgia in adults."

Fibromyalgia is a chronic rheumatic disease, characterized by widespread musculoskeletal pain and fatigue. It affects millions of people worldwide. Patients with fibromyalgia often also suffer from depression as a result of the impact the disease has on daily life.

Lyrica (pregabalin) has been approved by the FDA in the US and 139 other countries to treat the disorder and the drug helps to alleviate nerve pain in patients. In the US, Lyrica has also been approved to reduce neuropathic pain due to diabetic disorders, spinal cord injuries and neuralgia.

News of the test failure will add disappointment to what has already proven to be a difficult year for the New York-based drug maker, the biggest in the US, marked by patent expirations for key drugs and a stronger US dollar.

It is therefore crucial for Pfizer to find new avenues to generate revenue.

Over the past few years, Lyrica has been one of Pfizer’s biggest revenue generators. In 2013 alone, Lyrica sales topped US$4.6 billion, prompting Pfizer to identify additional applications for the drug.

Pfizer has also been expanding its vaccine product line-up through its own research and by looking out for related assets to acquire.

The company's shares were trading at US$33.83 per share, down 0.5 percent on Friday afternoon.

Copyright © Proactiveinvestors.com, 2015. All Rights Reserved

 

The above originally appeared here.

 


Arrow right

More Fibromyalgia News

 


 

blog comments powered by Disqus
Previous Previous Page